Nervous system disorders Uncommon: Headache Not known: Convulsions*, Dizziness Heart disease Not known: Palpitations Vascular pathologies Uncommon: Hypertension, Hypotension Respiratory, thoracic and mediastinal pathologies Not known: Dyspnea Gastrointestinal disorders Common: Vomiting, Nausea, Diarrhea, Abdominal pain Uncommon: Dysgeusia, Dyspepsia, Dry mouth Skin and subcutaneous tissue disorders Uncommon: Abnormal skin odor ** Not known: Itching, Skin rash Musculoskeletal and connective tissue disorders Uncommon: Muscle spasms Not known: Myasthenia***, Muscle tension Systemic disorders and conditions related to the administration site Uncommon: Chest pain, Feeling abnormal, Pyrexia, Injection site reaction**** Diagnostic tests Uncommon: Increased blood pressure Very rare: Increased INR*****
Neurochemistry Research
Controlled studies of fermentable fibers like oligofructose and an inulin-propionate ester have shown increases in plasma GLP-1 and PYY alongside improved satiety
Together, these two medications generated a total of 1.70 billion ($1.79 billion USD) in sales in 2022
[CrossRef] [PubMed] [Google Scholar] Role of diabetes and its metabolic pathways in epilepsy: An insight to various target approaches In: Naunyn-schmiedeberg's archives of pharmacology
At baseline, HIT-6 scores were significantly higher in the exenatide arm, and neither HIT-6 nor SF-36 showed significant changes over the course of the trial
